Valneva Shareholders Approve EGM Resolutions to Support Potential US IPO Plan
22 Décembre 2020 - 5:45PM
Saint-Herblain (France), December 22, 2020 –
Valneva SE (“Valneva” or “the Company”), a specialty vaccine
company focused on prevention against diseases with major unmet
needs, today announced that its shareholders approved the
resolutions recommended by the Management Board at its
Extraordinary General Meeting (EGM) held on December 22,
2020. Due to the COVID-19 pandemic, this EGM was held as a
closed meeting without the physical presence of shareholders.
Full voting results will be available on the Company’s website
within fifteen days.
Among the resolutions approved during the EGM
were delegations for the management board to increase the share
capital and/or to issue financial instruments.
Valneva called the EGM in order to obtain the
necessary authorizations to allow the Company to prepare for a
potential listing and public offering of American Depositary Shares
(each representing a number of the Company’s ordinary shares) on
Nasdaq in 2021 (the “Offering”), subject to market and other
conditions, consistent with the Company’s previously communicated
strategic plans. The timing, number of securities to be offered and
their price have not yet been determined. The Company plans to
submit a confidential draft registration statement to the
Securities and Exchange Commission (the “SEC”) in early 2021, and
the proposed Offering is expected to commence after the SEC
completes its review processes, subject to market and other
conditions. Shareholders and potential investors should note that
the proposed Offering may or may not proceed.
This press release is being made pursuant to,
and in accordance with, Rule 135 under the Securities Act of 1933,
as amended (the “Securities Act”). This press release does not
constitute an offer to sell or the solicitation of an offer to buy
securities, and shall not constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. The Company has several vaccines in
development including unique vaccines against Lyme disease,
COVID-19 and chikungunya. Valneva’s portfolio includes two
commercial vaccines for travelers: IXIARO®/JESPECT® indicated for
the prevention of Japanese encephalitis and DUKORAL® indicated for
the prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. Valneva has operations in Austria, Sweden,
the United Kingdom, France, Canada and the U.S. with over 500
employees.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the potential Offering. In addition, even
if the actual results or development of Valneva are consistent with
the forward-looking statements contained in this press release,
those results or developments of Valneva may not be indicative of
their in the future. In some cases, you can identify
forward-looking statements by words such as "could," "should,"
"may," "expects," "anticipates," "believes," "intends,"
"estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made in this press
release will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Please refer to the Universal Registration
Document filed with the Autorité des Marchés Financiers on March
30, 2020 under n° D.20-0217 for additional information in relation
to such factors, risks and uncertainties.
- 2020_12_22_VLA_Post_EGM_PR_EN_Final